Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression

ASIA unversity > 醫學暨健康學院 > 生物科技學系 > 期刊論文 > Item 310904400/16396

請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/16396

題名:	Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression
作者:	余永倫;Yu, Yung-luen;WEI, CHYOU-WEI;CHEN, YI-LIN;CHEN, MARK HUNG-CHIH;YIANG, GIOU-TENG
貢獻者:	生物科技學系
日期:	2010-02
上傳時間:	2012-11-23 09:12:31 (UTC+0)
摘要:	Recombinant adenovirus-associated vector serotype 2 (rAAV2) is one of the most promising gene transfer vectors due to its advantage of causing non-pathogenic infection, low immunogenicity, and long-term gene expression in human clinical trials. Human interleukin 15 (hIL15) has been implicated in modulation of antitumor activity of lymphokine-activated killer (LAK) cells, including T cells and NK cells. In this study, the rAAV2-hIL15 vector was produced and subjected for treatment with xenograft JC breast cancer model. Results showed that tumor onset was significantly delayed, the tumor growth was suppressed, and the lifespan of tumor-bearing mice were prolonged by rAAV2-hIL15. In addition, rAAV2-hIL15 was able to produce a substantial expression of IL15 protein that ultimately activated the cytotoxic activity of LAK cells. Furthermore, prominent apoptosis was observed in tumor lesions following injection of rAAV2-hIL15. Taken together, our results suggested that rAAV2-hIL15 appears as a new potential therapeutic tool for breast cancer immunotherapy.
關聯:	INTERNATIONAL JOURNAL OF ONCOLOGY
顯示於類別:	[生物科技學系] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	351	檢視/開啟

在ASIAIR中所有的資料項目都受到原著作權保護.